News

In this artist’s conception of the process, an automated deposition system places a new material onto a base material (purple beam, right) as the last sample that was made is analyzed and sent to the AI (green beams, brain, left). The AI tells the pulsed laser deposition machine what to do next (data cable, bottom).
Researchers harness AI for autonomous discovery and optimization of materials
Students gather at a poster session
Students acquire skills at Quantum Science Center
Rectangular box being lifted by a red pully system up the left side of the building
Researchers make ‘green’ floor to replace steel

Filter News

Area of Research

News Type

Date

News Topics

Media Contacts

Connect with ORNL

Miaofang Chi, a scientist in the Center for Nanophase Materials Sciences, received the 2021 Director’s Award for Outstanding Individual Accomplishment in Science and Technology. Credit: ORNL, U.S. Dept. of Energy

Microscopy innovator receives ORNL’s top science honor

A world-leading researcher in solid electrolytes and sophisticated electron microscopy methods received Oak Ridge National Laboratory’s top science honor today for her work in developing new materials for batteries. The announcement was made during a livestreamed Director’s Awards event hosted by ORNL Director Thomas Zacharia.

(From left) ORNL Associate Laboratory Director for Computing and Computational Sciences Jeff Nichols; ORNL Health Data Sciences Institute Director Gina Tourassi; DOE Deputy Under Secretary for Science Thomas Cubbage; ORNL Task Lead for Biostatistics Blair Christian; and ORNL Research Scientist Ioana Danciu were invited to the White House to showcase an ORNL-developed digital tool aimed at better matching cancer patients with clinical trials.

New ORNL AI tool revolutionizes process for matching cancer patients with clinical trials

OAK RIDGE, Tenn., March 4, 2019—A team of researchers from the Department of Energy’s Oak Ridge National Laboratory Health Data Sciences Institute have harnessed the power of artificial intelligence to better match cancer patients with clinical trials.